The Healthcare Fraud Prevention Partnership (HFPP) is constantly looking for ways to use the power of our combined resources to educate, inform, and improve our partners’ efforts to detect and prevent fraud, waste, and abuse. The HFPP, with support from its Partners, creates white papers to inform the public about pertinent issues that impact payers, providers, and patients.
Fraud, Waste, and Abuse in the Context of COVID-19
As a result of COVID-19, there were comprehensive changes to the nation’s healthcare system, creating potential vulnerabilities for healthcare fraud, waste, and abuse. In response, the HFPP developed this white paper which provides background on the impact of COVID-19, outlines associated schemes, and offers the latest methods to detect, mitigate, and prevent fraud, waste, and abuse related to the delivery of care for COVID-19.
Genetic Testing Fraud, Waste, and Abuse
The HFPP developed this paper in collaboration with Stanford University School of Medicine in response to the growing issue of fraud, waste, and abuse in genetic testing. The White Paper provides an overview of clinical genetic testing services, examines fraud, waste, and abuse schemes in the field of genetic testing, and presents possible actions that payers can take to address this issue.
Examining Clinical Laboratory Services
The HFPP examined clinical laboratory services, which can be a significant target for potential fraud and abuse. This White Paper explores systematic challenges that make laboratory services vulnerable to fraud and abuse, as well as describing specific types of fraud and abuse schemes identified by HFPP Partner organizations.
Reducing the Harms of Opioids
The HFPP has taken action to curb the nation’s opioid crisis. Learn what we are doing to reduce the harms of opioids while ensuring access to medically necessary therapies and reducing fraud, waste, and abuse.